Skip to main content
. 2018 Jun 30;8(6):e020427. doi: 10.1136/bmjopen-2017-020427

Table 4.

RUNX3

Author/year Patient no (P:NP) Methods Methylation threshold definition Statistical analysis Result
Boerwinkel et al 201443 44
(48:10)
Methylight methylation-specific PCR Previously published cut-off values applied to raw MSP data to calculate frequency of hypermethylation. RUNX3 cut-off=0.02 Mann-Whitney test Raw MSP values compared but no numerical value offered P versus NP not significantly differentially methylated
Jin et al 200941 195*
(50:145)
Methylation-specific PCR NMV=amount of methylated DNA compared with control beta-actin DNA generated by PCR Student’s t test and chi-squared test
AUROC
Hypermethylated in P
NMV 0.104:0.063
AUROC=0.671 (0.586, 0.756)
90% sensitivity
90% specificity P=0.0002
Sato et al 200840 62
(28:34)
Methylation-specific PCR NMV=amount of methylated DNA compared with control beta-actin DNA generated by PCR LDA, LOOCV, AUROC Hypermethylated in P
AUROC increment when added to segment length, histology and global methylation index=0.0216
90% sensitivity
90% specificity P=0.016
Schulmann et al 200539 53
(8:45)
Methylation-specific PCR NMV=amount of methylated DNA compared with control beta-actin DNA generated by PCR Cox proportional HRs Hypermethylated in P
OR=1.80 P=0.0267

*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).

AUROC, area under receiver operating characteristic; LDA, linear discriminant analysis; LOOCV, leave-one-out cross-validation; MSP, methylation specific PCR; NMV, normalised methylation value; NP, non-progressing patients; P, progressing patients.